Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Trazodone Hydrochloride

FDA-approved product (tablet, oral), marketed as Desyrel, Oleptro, Raldesy and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Trazodone Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Depressive disorder
  • Major depressive disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antidepressants
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA42.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Trazodone Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Trazodone Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Investigating the Effectiveness of E-CBTi Compared to Pharmaceutical Interventions in Treating Insomnia

    NCT05125146 · start 2021-11-01

    Registered record
    Registry ID
    NCT05125146
    Conditions
    Insomnia
    Interventions
    e-CBTi; Trazodone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2021-11-01
    Completion
    2025-12-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia
    Interventione-CBTi; Trazodone
    PhaseNot applicable
    Registry statusRecruiting

  • Obstructive Sleep Apnea and Arousal Threshold in Patients With Post-traumatic Stress Disorder

    NCT02699138 · start 2021-10

    Registered record
    Registry ID
    NCT02699138
    Conditions
    Sleep Apnea, Obstructive; Post-Traumatic Stress Disorders
    Interventions
    Trazodone; Placebo; Epiglottic catheter
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Withdrawn
    Start
    2021-10
    Completion
    2022-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSleep Apnea, Obstructive; Post-Traumatic Stress Disorders
    InterventionTrazodone; Placebo; Epiglottic catheter
    PhaseEarly phase 1
    Registry statusWithdrawn

  • National Adaptive Trial for PTSD Related Insomnia

    NCT03668041 · start 2021-02-25

    Registered record
    Registry ID
    NCT03668041
    Conditions
    Insomnia
    Interventions
    Trazodone; Eszopiclone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2021-02-25
    Completion
    2026-03-30
    Enrolment
    673

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia
    InterventionTrazodone; Eszopiclone; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Memory Enhancement by Gamma-hydroxybutyrate vs. Trazodone in Major Depressive Disorder.

    NCT04082806 · start 2020-08-06

    Registered record
    Registry ID
    NCT04082806
    Conditions
    Major Depressive Disorder
    Interventions
    GHB; Trazodone; Placebos
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-08-06
    Completion
    2022-04-06
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionGHB; Trazodone; Placebos
    PhasePhase 2
    Registry statusCompleted

  • Long-term Study With Trazodone Once-a-Day

    NCT04295941 · start 2020-06-23

    Registered record
    Registry ID
    NCT04295941
    Conditions
    Major Depressive Disorder
    Interventions
    TraZODone Hydrochloride 300 MG
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-06-23
    Completion
    2021-11-16
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionTraZODone Hydrochloride 300 MG
    PhaseNot recorded
    Registry statusCompleted

  • Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial

    NCT04302870 · start 2020-02-27

    Registered record
    Registry ID
    NCT04302870
    Conditions
    Motor Neuron Disease, Amyotrophic Lateral Sclerosis
    Interventions
    Memantine Hydrochloride Oral Solution; Trazodone Hydrochloride oral solution; Placebo oral solution; Amantadine Hydrochloride Oral Solution; Tacrolimus 1Mg Cap; Placebo capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2020-02-27
    Completion
    2030-12
    Enrolment
    1,150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMotor Neuron Disease, Amyotrophic Lateral Sclerosis
    InterventionMemantine Hydrochloride Oral Solution; Trazodone Hydrochloride oral solution; Placebo oral solution; Amantadine Hydrochloride Oral Solution +2 more
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Bioavailability Study of 300 mg Trazodone Hydrochloride (New Polymer) vs. 300 mg Trazodone Hydrochloride (Contramid® Prolonged-release Tablets) Under Fasting Conditions

    NCT05136521 · start 2020-02-17

    Registered record
    Registry ID
    NCT05136521
    Conditions
    Healthy
    Interventions
    Trazodone HCl - new polymer; Trazodone HCl - Contramid®
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-02-17
    Completion
    2020-07-19
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTrazodone HCl - new polymer; Trazodone HCl - Contramid®
    PhasePhase 1
    Registry statusCompleted

  • A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression

    NCT03852160 · start 2019-12-01

    Registered record
    Registry ID
    NCT03852160
    Conditions
    Depressive Disorder, Treatment-Resistant
    Interventions
    Esketamine 28 mg; Esketamine 56 mg; Esketamine 84 mg; Placebo; Escitalopram; Sertraline; Duloxetine; Mirtazapine; Agomelatine; Bupropion; Trazodone Prolonged Release
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2019-12-01
    Completion
    2021-07-25
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepressive Disorder, Treatment-Resistant
    InterventionEsketamine 28 mg; Esketamine 56 mg; Esketamine 84 mg; Placebo +7 more
    PhasePhase 3
    Registry statusWithdrawn

  • The Effect of Trazodone on the Severity of Obstructive Sleep Apnea in Insomnic Stroke Patients With Depression

    NCT04162743 · start 2019-02-01

    Registered record
    Registry ID
    NCT04162743
    Conditions
    Sleep Apnea Syndromes; Cerebral Infarction
    Interventions
    Trazodone; Placebo oral tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-02-01
    Completion
    2020-03-31
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSleep Apnea Syndromes; Cerebral Infarction
    InterventionTrazodone; Placebo oral tablet
    PhasePhase 4
    Registry statusCompleted

  • Trazodone/Gabapentin Fixed Dose Combination Products in Painful Diabetic Neuropathy

    NCT03749642 · start 2018-11-22

    Registered record
    Registry ID
    NCT03749642
    Conditions
    Painful Diabetic Neuropathy
    Interventions
    trazodone/gabapentin 2.5/25 mg; trazodone/gabapentin 5/50 mg; trazodone/gabapentin 10/100; Gabapentin; Placebo oral capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-11-22
    Completion
    2020-06-06
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPainful Diabetic Neuropathy
    Interventiontrazodone/gabapentin 2.5/25 mg; trazodone/gabapentin 5/50 mg; trazodone/gabapentin 10/100; Gabapentin +1 more
    PhasePhase 2
    Registry statusCompleted

  • Accuracy and Efficacy of Trazodone (Desyrel) on Sleep Quality and Pain Management of TMD Patient

    NCT03522207 · start 2018-10-15

    Registered record
    Registry ID
    NCT03522207
    Conditions
    TMD; Sleep Bruxism; TMJ Pain; Chronic Pain; Sleep Disorder
    Interventions
    polysomnography; Trazodone; Placebos; polysomnography; Trazodone; placebos; polysomnography
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2018-10-15
    Completion
    2020-01-20
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTMD; Sleep Bruxism; TMJ Pain; Chronic Pain +1 more
    Interventionpolysomnography; Trazodone; Placebos; polysomnography +3 more
    PhasePhase 4
    Registry statusTerminated

  • Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

    NCT03511118 · start 2018-10-04

    Registered record
    Registry ID
    NCT03511118
    Conditions
    Lactating Women on Select DOI; Breastfed Infants of Mothers on Select DOI
    Interventions
    Tranexamic acid (TXA); labetalol; metformin; nifedipine; clindamycin; oxycodone; azithromycin; escitalopram; sertraline; ondansetron; Ciprofloxacin; Doxycycline; Levofloxacin; Methylphenidate; Sumatriptan; Citalopram; Cyclobenzaprine; Furosemide; Gabapentin; Hydrochlorothiazide; Hydroxyurea; Rosuvastatin; Topiramate; Trazodone; Valganciclovir; Venlafaxine; Verapamil; Remdesivir; Anakinra; Tocilizumab; Fluvoxamine; Amoxicillin; Bupropion; Duloxetine; Hydrocodone; Levetiracetam; Paroxetine; Buprenorphine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2018-10-04
    Completion
    2028-07-31
    Enrolment
    1,600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLactating Women on Select DOI; Breastfed Infants of Mothers on Select DOI
    InterventionTranexamic acid (TXA); labetalol; metformin; nifedipine +34 more
    PhaseNot recorded
    Registry statusRecruiting

  • Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis

    NCT03534284 · start 2018-09-19

    Registered record
    Registry ID
    NCT03534284
    Conditions
    Insomnia; End Stage Renal Disease
    Interventions
    Cognitive Behavioral Therapy for Insomnia; Trazodone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-09-19
    Completion
    2022-11-17
    Enrolment
    126

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia; End Stage Renal Disease
    InterventionCognitive Behavioral Therapy for Insomnia; Trazodone; Placebo
    PhasePhase 3
    Registry statusCompleted

  • PK Study of Multi-dose Trazodone Hydrochloride Prolonged-released Tablets in Healthy Chinese

    NCT02785614 · start 2017-05-01

    Registered record
    Registry ID
    NCT02785614
    Conditions
    Depression
    Interventions
    trazodone hydrochloride prolonged-release tablet; trazodone hydrochloride tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-05-01
    Completion
    2018-01-04
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression
    Interventiontrazodone hydrochloride prolonged-release tablet; trazodone hydrochloride tablet
    PhasePhase 1
    Registry statusCompleted

  • Trazodone Dose Tolerance and APAP Adherence

    NCT02945644 · start 2017-02-13

    Registered record
    Registry ID
    NCT02945644
    Conditions
    Sleep Apnea, Obstructive
    Interventions
    Trazodone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Suspended
    Start
    2017-02-13
    Completion
    2020-12
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSleep Apnea, Obstructive
    InterventionTrazodone; Placebo
    PhasePhase 1
    Registry statusSuspended